412 related articles for article (PubMed ID: 25838291)
1. In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.
Sibiude J; Le Chenadec J; Bonnet D; Tubiana R; Faye A; Dollfus C; Mandelbrot L; Delmas S; Lelong N; Khoshnood B; Warszawski J; Blanche S;
Clin Infect Dis; 2015 Jul; 61(2):270-80. PubMed ID: 25838291
[TBL] [Abstract][Full Text] [Related]
2. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry.
Vannappagari V; Albano JD; Koram N; Tilson H; Scheuerle AE; Napier MD
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():6-10. PubMed ID: 26687320
[TBL] [Abstract][Full Text] [Related]
3. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
Brogly SB; Ylitalo N; Mofenson LM; Oleske J; Van Dyke R; Crain MJ; Abzug MJ; Brady M; Jean-Philippe P; Hughes MD; Seage GR
AIDS; 2007 May; 21(8):929-38. PubMed ID: 17457086
[TBL] [Abstract][Full Text] [Related]
4. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J;
Clin Infect Dis; 2013 Sep; 57(6):891-902. PubMed ID: 23766338
[TBL] [Abstract][Full Text] [Related]
6. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
7. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Williams PL; Yildirim C; Chadwick EG; Van Dyke RB; Smith R; Correia KF; DiPerna A; Seage GR; Hazra R; Crowell CS;
Lancet HIV; 2020 Jan; 7(1):e49-e58. PubMed ID: 31740351
[TBL] [Abstract][Full Text] [Related]
8. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.
Culnane M; Fowler M; Lee SS; McSherry G; Brady M; O'Donnell K; Mofenson L; Gortmaker SL; Shapiro DE; Scott G; Jimenez E; Moore EC; Diaz C; Flynn PM; Cunningham B; Oleske J
JAMA; 1999 Jan; 281(2):151-7. PubMed ID: 9917118
[TBL] [Abstract][Full Text] [Related]
9. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
[TBL] [Abstract][Full Text] [Related]
10. Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.
Briand N; Le Coeur S; Traisathit P; Karnchanamayul V; Hansudewechakul R; Ngampiyasakul C; Bhakeecheep S; Ithisukanan J; Hongsiriwon S; McIntosh K; Lallemant M
Pediatr Infect Dis J; 2006 Apr; 25(4):325-32. PubMed ID: 16567984
[TBL] [Abstract][Full Text] [Related]
11. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
[TBL] [Abstract][Full Text] [Related]
12. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
[TBL] [Abstract][Full Text] [Related]
13. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?
Briand N; Warszawski J; Mandelbrot L; Dollfus C; Pannier E; Cravello L; Nguyen R; Matheron I; Winer N; Tubiana R; Rouzioux C; Faye A; Blanche S;
Clin Infect Dis; 2013 Sep; 57(6):903-14. PubMed ID: 23728147
[TBL] [Abstract][Full Text] [Related]
14. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.
Thorne C; Newell ML
Med Wieku Rozwoj; 2003; 7(4 Pt 1):425-36. PubMed ID: 15010553
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
17. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
Simon A; Warszawski J; Kariyawasam D; Le Chenadec J; Benhammou V; Czernichow P; Foissac F; Laborde K; Tréluyer JM; Firtion G; Layouni I; Munzer M; Bavoux F; Polak M; Blanche S;
JAMA; 2011 Jul; 306(1):70-8. PubMed ID: 21730243
[TBL] [Abstract][Full Text] [Related]
18. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.
Lallemant M; Jourdain G; Le Coeur S; Kim S; Koetsawang S; Comeau AM; Phoolcharoen W; Essex M; McIntosh K; Vithayasai V
N Engl J Med; 2000 Oct; 343(14):982-91. PubMed ID: 11018164
[TBL] [Abstract][Full Text] [Related]
19. Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis.
Tshivuila-Matala COO; Honeyman S; Nesbitt C; Kirtley S; Kennedy SH; Hemelaar J
AIDS; 2020 Sep; 34(11):1643-1656. PubMed ID: 32701581
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
Mandelbrot L; Landreau-Mascaro A; Rekacewicz C; Berrebi A; Bénifla JL; Burgard M; Lachassine E; Barret B; Chaix ML; Bongain A; Ciraru-Vigneron N; Crenn-Hébert C; Delfraissy JF; Rouzioux C; Mayaux MJ; Blanche S;
JAMA; 2001 Apr; 285(16):2083-93. PubMed ID: 11311097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
